Liver Cancer Awareness Month 2024

Viral hepatitis infection is the most common risk factor for liver cancer. Chronic viral hepatitis can lead to hepatocellular carcinoma (HCC), which accounts for 80% of all liver cancer cases and is the third most common cause of cancer deaths worldwide.

A report from the Centre for Disease Analysis (CDA) Foundation* finds that individuals living with hepatitis B and C have a significantly higher risk of developing cancer than someone smoking one pack of cigarettes per day.  

Despite this, nearly half (42%) of people globally are not aware that one of the leading causes of liver cancer is viral hepatitis – according to research by the World Hepatitis Alliance**.

This October, for Liver Cancer Awareness Month, the hepatitis and the cancer communities must come together to raise their collective voice to increase awareness of liver cancer’s connection to viral hepatitis and call for greater action.

Hepatitis vaccination, testing, treatment and care should be integrated into national cancer prevention and control strategies and programmes. Hepatitis B and C should be “considered as cancer causing infections and international guidelines should be reconsidered accordingly” (CDA).

Get involved this Liver Cancer Awareness Month

This October, download and promote the Liver Cancer Awareness month assets below and help to raise awareness of liver cancer’s connection to viral hepatitis and call for greater action.

We also have a customisable tool which you can use to create your own assets here.

We also developed an advocacy briefing to support advocates in their work to improve understanding of the links between hepatitis and liver cancer. It includes calling for countries to invest in hepatitis services to reduce the burden of NCDs and urging the hepatitis and cancer communities to come together to raise their collective voice to increase awareness.

Our Community Impact Programme (CIP) e-learning now includes a new module on hepatitis and liver cancer. Developed with experts in the field, it provides further information on liver cancer, the role of hepatitis elimination in preventing liver cancer, and how you can take action.

The e-learning is open to all, and you can access the modules in English, French, and Spanish.

Download the full Liver Cancer Awareness Month WHA communications toolkit below.

Webinar: We’re not waiting – Beating hepatitis and cancer together 

On Thursday 27 July 2023, WHA hosted a webinar to discuss the integration of the hepatitis community and hepatitis services with liver cancer and NCDs to beat hepatitis and liver cancer together. Chaired by our director, Jessica Hicks, speakers included: 

  • Rosie Tasker, Global Advocacy Manager, Union for International Cancer Control (UICC)  
  • Devin Razavi-Shearer, Associate Director, HBV/HDV, Center for Disease Analysis Foundation  
  • Dr Nafiisah Chotun, Programme Lead, Endemic and NTDs & RISLNET Coordinator Southern African region, Africa Centres for Disease Control and Prevention (Africa CDC)  
  • Milan Mishkovikj, Director, European Liver Patients’ Assocation (ELPA)  
  • Wendy Wang, Deputy Director, Liver Disease Prevention and Treatment Research Foundation, Taiwan 

* Razavi, H. CDA Foundation, 2023. Risk of developing cancer – comparison of HBV, HCV, and smoking. DOI: 10.3252/pso.eu.EASLCONGRESS.2023 

** Global survey of 569 respondents from: Argentina, Germany, Ghana, Hong Kong, India, Nigeria, South Korea, Vietnam, and the United States of America. Participants sourced by SurveyMonkey Audience from 30 June to 4 July, 2023. Research conducted by the World Hepatitis Alliance (WHA) 

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close